Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Breast J ; 23(5): 519-524, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28323373

ABSTRACT

We evaluated whether mental illness is a barrier to genetic counseling for hereditary breast and ovarian cancer (HBOC) in multiethnic breast cancer patients. We conducted a retrospective analysis of 308 women with newly diagnosed breast cancer and eligible for HBOC genetic testing seen in the breast clinic of an academic, urban medical center from 2007 to 2015. Uptake of genetic services and history of mental health disorder (MHD), defined as a psychiatric diagnosis or treatment with an antidepressant, mood stabilizer, anxiolytic, or antipsychotic medication, were ascertained by medical chart review. The mean age at breast cancer diagnosis was 56 years, with 44% non-Hispanic whites, 37% Hispanics, and 15% non-Hispanic blacks. Ninety-nine (32%) women met study criteria for MHD, 73% had a genetics referral, 57% had genetic counseling, and 54% completed BRCA testing. Uptake of genetic counseling services did not differ by race/ethnicity or presence of MHD. In multivariable analysis, younger age at diagnosis, Ashkenazi Jewish heritage, and family history of breast cancer were associated with HBOC genetic counseling. A relatively high proportion of breast cancer patients eligible for HBOC genetic testing were referred to a genetic counselor and referral status did not vary by MHD or race/ethnicity.


Subject(s)
Breast Neoplasms/psychology , Genetic Predisposition to Disease , Mental Disorders/epidemiology , Ovarian Neoplasms/psychology , Aged , Breast Neoplasms/ethnology , Breast Neoplasms/genetics , Cohort Studies , Ethnicity , Female , Genetic Counseling , Humans , Mental Disorders/ethnology , Mental Disorders/psychology , Middle Aged , New York City/epidemiology , Ovarian Neoplasms/ethnology , Ovarian Neoplasms/genetics , Surveys and Questionnaires
2.
Cancer Prev Res (Phila) ; 10(8): 434-441, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28611039

ABSTRACT

Women with atypical hyperplasia and lobular or ductal carcinoma in situ (LCIS/DCIS) are at increased risk of developing invasive breast cancer. Chemoprevention with selective estrogen receptor modulators or aromatase inhibitors can reduce breast cancer risk; however, uptake is estimated to be less than 15% in these populations. We sought to determine which factors are associated with chemoprevention uptake in a population of women with atypical hyperplasia, LCIS, and DCIS. Women diagnosed with atypical hyperplasia/LCIS/DCIS between 2007 and 2015 without a history of invasive breast cancer were identified (N = 1,719). A subset of women (n = 73) completed questionnaires on breast cancer and chemoprevention knowledge, risk perception, and behavioral intentions. Descriptive statistics were generated and univariate and multivariable log-binomial regression were used to estimate the association between sociodemographic and clinical factors and chemoprevention uptake. In our sample, 29.3% had atypical hyperplasia, 23.3% had LCIS, and 47.4% had DCIS; 29.4% used chemoprevention. Compared with women with atypical hyperplasia, LCIS [RR, 1.43; 95% confidence interval (CI), 1.16-1.76] and DCIS (RR, 1.54; 95% CI, 1.28-1.86) were significantly associated with chemoprevention uptake, as was medical oncology referral (RR, 5.79; 95% CI, 4.80-6.98). Younger women were less likely to take chemoprevention (RR, 0.61; 95% CI, 0.42-0.87), and there was a trend toward increased uptake in Hispanic compared with non-Hispanic white women. The survey data revealed a strong interest in learning about chemoprevention, but there were misperceptions in personal breast cancer risk and side effects of chemoprevention. Improving communication about breast cancer risk and chemoprevention may allow clinicians to facilitate informed decision-making about preventative therapy. Cancer Prev Res; 10(8); 434-41. ©2017 AACR.


Subject(s)
Breast Carcinoma In Situ/drug therapy , Breast Neoplasms/prevention & control , Chemoprevention/psychology , Health Knowledge, Attitudes, Practice , Adult , Aged , Aged, 80 and over , Aromatase Inhibitors/therapeutic use , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Lobular/drug therapy , Chemoprevention/statistics & numerical data , Cohort Studies , Female , Humans , Hyperplasia/drug therapy , Middle Aged , Retrospective Studies , Selective Estrogen Receptor Modulators/therapeutic use , Surveys and Questionnaires , Young Adult
3.
AMIA Annu Symp Proc ; 2016: 411-420, 2016.
Article in English | MEDLINE | ID: mdl-28269836

ABSTRACT

Chemoprevention with antiestrogens could decrease the incidence of invasive breast cancer but uptake has been low among high-risk women in the United States. We have designed a web-based patient-facing decision aid, called RealRisks, to inform high-risk women about the risks and benefits of chemoprevention and facilitate shared decision-making with their primary care provider. We conducted two rounds of usability testing to determine how subjects engaged with and understood the information in RealRisks. A total of 7 English-speaking and 4 Spanish-speaking subjects completed testing. Using surveys, think-aloud protocols, and subject recordings, we identified several themes relating to the usability of RealRisks, specifically in the content, ease of use, and navigability of the application. By conducting studies in two languages with a diverse multi-ethnic population, we were able to implement interface changes to make RealRisks accessible to users with varying health literacy and acculturation.


Subject(s)
Breast Neoplasms/ethnology , Decision Making , Decision Support Techniques , Internet , Risk Assessment/methods , Female , Health Literacy , Hispanic or Latino , Humans , Patient Satisfaction , United States , User-Computer Interface
SELECTION OF CITATIONS
SEARCH DETAIL